Original Publication Date: 16 January, 2015
Publication / Source: Future Oncology
Authors: Edurne Arriola, Noemi Reguart, Angel Artal et al.
Afatinib is an irreversible ErbB family blocker tyrosine kinase inhibitor (TKI), which has recently been approved for the treatment of patients with EGFR M+ non-small cell lung cancer. As observed with reversible EGFR TKIs, it can induce class-effect adverse events. Appropriate management of afatinib-related adverse events improves quality of life and clinical outcomes in these patients. Here we provide practical recommendations for the prophylaxis and treatment of the most common of these (e.g., diarrhea, rash, mucositis and others).
Click here to view the full article in Future Oncology.